<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Bone and soft tissue sarcomas, tumors of the skin</journal-id><journal-title-group><journal-title xml:lang="en">Bone and soft tissue sarcomas, tumors of the skin</journal-title><trans-title-group xml:lang="ru"><trans-title>Саркомы костей, мягких тканей и опухоли кожи</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2219-4614</issn><issn publication-format="electronic">2782-3687</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">169</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>BONE SARCOMAS</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>САРКОМЫ КОСТЕЙ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Role of receptor-ligand system in giant cell tumor</article-title><trans-title-group xml:lang="ru"><trans-title>Роль VEGF рецептор-лигандной системы при гигантоклеточной опухоликости</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Stepanova</surname><given-names>E. V.</given-names></name><name xml:lang="ru"><surname>Степанова</surname><given-names>Е. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>e_stepanova@nm.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Musaev</surname><given-names>E. R.</given-names></name><name xml:lang="ru"><surname>Мусаев</surname><given-names>Э. Р.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Sushencov</surname><given-names>E. A.</given-names></name><name xml:lang="ru"><surname>Сушенцов</surname><given-names>Е. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Petrovichev</surname><given-names>N. N.</given-names></name><name xml:lang="ru"><surname>Петровичев</surname><given-names>Н. Н.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Aliev</surname><given-names>M. D.</given-names></name><name xml:lang="ru"><surname>Алиев</surname><given-names>М. Д.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Lichinizer</surname><given-names>M. R.</given-names></name><name xml:lang="ru"><surname>Личиницер</surname><given-names>М. Р.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences</institution></aff><aff><institution xml:lang="ru">Российский онкологический научный центр им. Н.Н. Блохина РАМН</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2010-06-11" publication-format="electronic"><day>11</day><month>06</month><year>2010</year></pub-date><volume>2</volume><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>34</fpage><lpage>38</lpage><history><date date-type="received" iso-8601-date="2022-01-11"><day>11</day><month>01</month><year>2022</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2010, Stepanova E.V., Musaev E.R., Sushencov E.A., Petrovichev N.N., Aliev M.D., Lichinizer M.R.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2010, Степанова Е.В., Мусаев Э.Р., Сушенцов Е.А., Петровичев Н.Н., Алиев М.Д., Личиницер М.Р.</copyright-statement><copyright-year>2010</copyright-year><copyright-holder xml:lang="en">Stepanova E.V., Musaev E.R., Sushencov E.A., Petrovichev N.N., Aliev M.D., Lichinizer M.R.</copyright-holder><copyright-holder xml:lang="ru">Степанова Е.В., Мусаев Э.Р., Сушенцов Е.А., Петровичев Н.Н., Алиев М.Д., Личиницер М.Р.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://sarbon.abvpress.ru/jour/article/view/169">https://sarbon.abvpress.ru/jour/article/view/169</self-uri><abstract xml:lang="en"><p>Expression of VEGF and its receptors and proliferative activities were studied in cells of giant cell tumor of the bone. Immuno-histochemical analysis was performed on 11 formalin-fixed, formalin-embedded samples of giant cell tumor of the bone. VEGF and its receptors VEGFR-1 (Flt-1) and VEGFR-2 (Flk-l/KDR) was detected in all specimens and all cellular components such as reactive osteoclast-like giant cells and stromal cells. Ki-67 expression was limited to the mononuclear stromal cell component of the tumors. The high degree of expression Flk-1 and Flt-1 significantly correlated with high proliferative activity of the tumor (≥5 %) (p=0,031 for Flk-1 and p=0,048 for Flt-1). These results suggest that VEGF receptor-ligand system might play a role in the pathogenesis of giant cell tumor of the bone. The further research should help to explain a unique nature and cell interaction mechanisms of this tumor.</p></abstract><trans-abstract xml:lang="ru"><p>Было проведено исследование экспрессии VEGF и его рецепторов и пролиферативной активности в клетках гигантоклеточной опухоли кости. Иммуногистохимическим методом было исследовано 11 фиксированных в формалине, заключенных в формалин образцов гигантоклеточной опухоли. VEGF и его рецепторы VEGFR-1 (Fit-1) and VEGFR-2 (Flk-1 /KDR) были обнаружены во всех случаях и во всех клеточных типах, как на многоядерных остеокласт-подобных клетках, так и на стромальных. Стромальный компонент опухоли был единственным типом клеток, окрашивающихся на Кi-67. Высокая степень экспрессии Flk-І и FIt-І значимо коррелировала с высокой пролиферативной активностью (≥5%) (р=0,031 и р=0,048, соответственно). Полученные результаты предполагают важную роль VEGF рецептор-лигандной системы в патогенезе гигантоклеточной опухоли кости. Дальнейшие исследования в этой области должны помочь прояснить уникальную природу и механизмы взаимодействий клеток этой опухоли.</p></trans-abstract><kwd-group xml:lang="en"><kwd>VEGFR</kwd><kwd>giant cell tumor</kwd><kwd>angiogenesis</kwd><kwd>VEGER</kwd><kwd>osteoclasts</kwd><kwd>bone sarcomas</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>гигантоклеточная опухоль</kwd><kwd>ангиогенез</kwd><kwd>остеокласты</kwd><kwd>саркомы костей</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Abe Y., Yonemura K., Nishida K., Takagi K. Giant cell tumor of bone: analysis of proliferative cells by double-labeling immunohistochemistry with anti-proliferating cell nuclear antigen antibody and culture procedure. Nippon Seikeigeka Gakkai Zasshi. 1994, v. 68, p. 407-414.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Atkins G.J., Kostakis P., Vincent C. et al. RANK Expression as a cell surface marker of human osteoclast precursors in peripheral blood, bone marrow, and giant cell tumors of bone. J. Bone Miner Res. 2006, v. 21, p. 1339-1349.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Barleon B., Sozzani S., Zhou D. et al. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood. 1996. v. 87. p. 3336-3343.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Cheng J.C., Johnston J.O. Giant cell tumor of bone. Prognosis and treatment of pulmonary metastases. Clin. Orthop. Relat. Res. 1997, v. 338, p. 205-214.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Chuong R., Kaban L.B., Kozakewich H. Central giant cell lesions of thejaws: clinicopathologic study. J. Oral Maxillofac Surg. 1986, v. 44, p. 708-713.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Clauss M., Weich H., Breier G. et al. The vascular endothelial growth factor receptor Flt-1 mediates biological activities. Implications of functional role of placenta growth factor in monocyte activation and chemotaxis. J. Biol. Chem. 1996, v. 271, p. 17629-17634.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Ismail F.W., Shamsudin A.M., Wan Z. et al. Кi67 immunohistochemistry index in stage III giant cell tumor of the bone. J. Exp. Clin. Cancer Res. 2010, v. 12, p. 29-25.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Lau Y.S., Sabokbar A., Gibbons C.L. et al. Phenotypic and molecular studies of giant-cell tumors of bone and soft tissue. Hum. Pathol. 2005, v. 36. p. 945-954.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Liao T.S., Yurgelun M.B., Chang S.S. et al. Recruitment of osteoclast precursors by stromal cell derived factor-1 (SDF-1) in giant cell tumor of bone. J. Orthop. Res. 2005, v. 23, p. 203-209.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Mills B.G., Frausto A. Cytokines expressed in multinucleated cells. Paget’s disease and giant cell tumors versus normalbone. Calcif Tissue Int. 1997, 61, p. 16-21.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Morgan T., Atkins G.J., Trivett M.K. et al. Molecular profiling of giant cell tumor of bone and the osteoclastic localization of ligand for receptor activator of nuclear factor kappa-B. Am. J. Pathol. 2005, v. 167, p. 117-128.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Niida S., Kaku M., Amano H. et al. Vascular endothelial growth factor can substitute for macrophage colony-stimulating factor in the support of osteoclastic bone resorption. J. Exp. Med. 1999, v. 190, p. 293-298.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Robinson D., Einhorn T.A. Giant cell tumor of bone: a unique paradigm of stromal hemapoietic cellular interactions. J. Cell Biochem. 1994, v. 55, p. 300-303.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Robinson D., Segal M., Nevo Z. Giant cell tumor of bone. The role of fibroblast growth factor 3 positive mesenchymal stem cells in its pathogenesis Pathobiology. 2002-2003, v. 70, p. 333-342.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Rosai J., Ackerman L.V. Bones and Joints. In Rosai J. (Ed): Surgical Pathology. Mosby, St. Louis. 2004, p. 2169-2172.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Roux S., Quinn J., Pichaud F. et al. Human cord blood monocytes undergo terminal osteoclast differentiation in vitro in the presence of culture medium conditioned by giant cell tumor of bone. J. Cell Physiol. 1996, v. 168, p. 489-498.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Werner M. Giant cell tumor of bone: morphological, biological and histogenetical aspects. Int. Orthop. 2006, v. 30, p. 484-489.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Wülling M., Delling G., Kaiser E. The origin of the neoplastic stromal cell in giant cell tumor of bone. Hum. Pathol. 2003, v. 34 (10), p. 983-993.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Zheng M.H., Robbins P., Xu J. et al. The histogenesis of giant cell tumor of bone: a model of interaction between neoplastic cells and osteoclasts. Histol Histopathol. 2001, v. 16, p. 297-307.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Zheng M.H., Xu J., Robbins P. et al. Gene expression of vascular endothelial growth factor in giant cell tumors of bone. Hum. Pathol. 2000, v. 31, p. 804-812.</mixed-citation></ref></ref-list></back></article>
